SK Biopharmaceuticals Co., Ltd.

KOSE:A326030 Stock Report

Market Cap: ₩9.1t

SK Biopharmaceuticals Valuation

Is A326030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A326030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₩162.62k
Fair Value
29.2% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: A326030 (₩115100) is trading below our estimate of fair value (₩162621.36)

Significantly Below Fair Value: A326030 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A326030?

Key metric: As A326030 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A326030. This is calculated by dividing A326030's market cap by their current revenue.
What is A326030's PS Ratio?
PS Ratio17.6x
Sales₩511.33b
Market Cap₩9.05t

Price to Sales Ratio vs Peers

How does A326030's PS Ratio compare to its peers?

The above table shows the PS ratio for A326030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.4x
A000100 Yuhan
4.6x8.6%₩9.1t
A000250 Sam Chun Dang Pharm
20.1xn/a₩4.2t
A128940 Hanmi Pharm
2.3x8.2%₩3.4t
A009420 Hanall Biopharma
14.8x18.9%₩1.9t
A326030 SK Biopharmaceuticals
17.6x23.5%₩9.1t

Price-To-Sales vs Peers: A326030 is expensive based on its Price-To-Sales Ratio (17.6x) compared to the peer average (10.5x).

Price to Sales Ratio vs Industry

How does A326030's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$158.48m
A002620 Jeil Pharma Holdings
0.1xn/aUS$78.76m
A000230 Ildong Holdings
0.1xn/aUS$51.86m
No more companies available in this PS range
A326030 17.6xIndustry Avg. 0.8xNo. of Companies14PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A326030 is expensive based on its Price-To-Sales Ratio (17.6x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A326030's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A326030 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.6x
Fair PS Ratio8.6x

Price-To-Sales vs Fair Ratio: A326030 is expensive based on its Price-To-Sales Ratio (17.6x) compared to the estimated Fair Price-To-Sales Ratio (8.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A326030 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩115,100.00
₩139,470.59
+21.2%
19.7%₩170,000.00₩61,000.00n/a17
Feb ’26₩109,100.00
₩125,400.00
+14.9%
19.9%₩150,000.00₩61,000.00n/a15
Jan ’26₩111,100.00
₩123,357.14
+11.0%
20.7%₩150,000.00₩57,000.00n/a14
Dec ’25₩103,400.00
₩123,250.00
+19.2%
19.5%₩150,000.00₩57,000.00n/a16
Nov ’25₩114,400.00
₩109,428.57
-4.3%
20.9%₩140,000.00₩57,000.00n/a14
Oct ’25₩104,000.00
₩108,500.00
+4.3%
21.1%₩140,000.00₩54,000.00n/a14
Sep ’25₩115,000.00
₩107,785.71
-6.3%
20.7%₩140,000.00₩54,000.00n/a14
Aug ’25₩87,100.00
₩107,437.50
+23.3%
20.1%₩130,000.00₩54,000.00n/a16
Jul ’25₩78,900.00
₩107,437.50
+36.2%
20.1%₩130,000.00₩54,000.00n/a16
Jun ’25₩85,400.00
₩106,400.00
+24.6%
21.1%₩130,000.00₩51,000.00n/a15
May ’25₩87,600.00
₩106,133.33
+21.2%
21.5%₩130,000.00₩51,000.00n/a15
Apr ’25₩92,000.00
₩103,400.00
+12.4%
21.6%₩130,000.00₩50,000.00n/a15
Mar ’25₩96,900.00
₩105,062.50
+8.4%
21.4%₩130,000.00₩50,000.00n/a16
Feb ’25₩90,000.00
₩105,062.50
+16.7%
21.4%₩130,000.00₩50,000.00₩109,100.0016
Jan ’25₩100,400.00
₩105,333.33
+4.9%
21.6%₩130,000.00₩54,000.00₩111,100.0015
Dec ’24₩85,300.00
₩105,333.33
+23.5%
21.6%₩130,000.00₩54,000.00₩103,400.0015
Nov ’24₩75,600.00
₩105,266.67
+39.2%
21.9%₩130,000.00₩54,000.00₩114,400.0015
Oct ’24₩86,200.00
₩106,785.71
+23.9%
20.2%₩130,000.00₩65,000.00₩104,000.0014
Sep ’24₩82,100.00
₩106,266.67
+29.4%
19.7%₩130,000.00₩65,000.00₩115,000.0015
Aug ’24₩90,000.00
₩96,714.29
+7.5%
13.3%₩110,000.00₩65,000.00₩87,100.0014
Jul ’24₩80,900.00
₩94,923.08
+17.3%
13.5%₩110,000.00₩65,000.00₩78,900.0013
Jun ’24₩74,700.00
₩95,285.71
+27.6%
13.1%₩110,000.00₩65,000.00₩85,400.0014
May ’24₩69,000.00
₩94,692.31
+37.2%
16.5%₩110,000.00₩51,000.00₩87,600.0013
Apr ’24₩63,300.00
₩94,692.31
+49.6%
16.5%₩110,000.00₩51,000.00₩92,000.0013
Mar ’24₩66,700.00
₩95,500.00
+43.2%
18.3%₩120,000.00₩51,000.00₩96,900.0012
Feb ’24₩71,600.00
₩95,916.67
+34.0%
18.4%₩120,000.00₩51,000.00₩90,000.0012
Analyst Price Target
Consensus Narrative from 17 Analysts
₩139.47k
Fair Value
17.5% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 16:01
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SK Biopharmaceuticals Co., Ltd. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dae Woong YooBookook Securities Co. Ltd
Heejin LimCitigroup Inc
Citi ResearchCitigroup Inc